Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca loses comms head

Neil McCrae to join UK’s Royal Mail
AstraZeneca - Neil McCrae

AstraZeneca (AZ) has lost its VP of global communications to the UK's Royal Mail.

After almost two decades in the pharmaceutical sector, including six years with AZ, Neil McCrae will take up his new role on April 1.

Joining AstraZeneca in 2008 from GlaxoSmithKline (GSK), McCrae held a number of roles within the business, including vice-president of corporate communications and head of global media relations.

Prior to joining SmithKline Beecham, GSK's predecessor, in 1996, he part-owned the communications agency Design Publications.

"We wish Neil all the best in his new role,” said AstraZeneca's head of global media relations Esra Erkal-Paler.

Erkal-Paler said she was not yet able to say how AstraZeneca would place McCrae, or whether his departure would have any impact on the role of interim executive vice-president of human resources and corporate affairs Caroline Hempstead.

McCrae's remit at the Royal Mail will include media relations, internal communications, public affairs, corporate responsibility and community investment.

4th March 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics